Fennec Pharmaceuticals Inc. (TSE:FRX – Get Free Report)’s stock price reached a new 52-week high during trading on Monday. The company traded as high as C$18.35 and last traded at C$18.35, with a volume of 591 shares trading hands. The stock had previously closed at C$16.56.
Fennec Pharmaceuticals Stock Performance
The stock has a market cap of C$646.20 million, a PE ratio of -152.92 and a beta of 3.90. The company has a 50 day moving average of C$14.97 and a two-hundred day moving average of C$13.02.
Insider Activity
In other Fennec Pharmaceuticals news, insider Pierre Sayad sold 12,000 shares of the business’s stock in a transaction that occurred on Friday, September 4th. The stock was sold at an average price of C$17.18, for a total transaction of C$206,160.00. Following the completion of the sale, the insider directly owned 9,519 shares in the company, valued at approximately C$163,536.42. The trade was a 55.76% decrease in their position. Also, insider Robert Christopher Andrade sold 106,844 shares of the stock in a transaction that occurred on Thursday, August 27th. The shares were sold at an average price of C$16.63, for a total value of C$1,776,815.72. Following the transaction, the insider directly owned 217,675 shares of the company’s stock, valued at C$3,619,935.25. The trade was a 32.92% decrease in their position. 16.20% of the stock is owned by corporate insiders.
Institutional Trading of Fennec Pharmaceuticals
An institutional investor recently bought a new stake in Fennec Pharmaceuticals stock. Cornerstone Capital Inc. acquired a new stake in Fennec Pharmaceuticals Inc. (TSE:FRX – Free Report) in the 2nd quarter, according to its most recent Form 13F filing with the SEC. The institutional investor acquired 105,000 shares of the biopharmaceutical company’s stock, valued at approximately $1,129,000. Cornerstone Capital Inc. owned about 0.30% of Fennec Pharmaceuticals as of its most recent filing with the SEC. Hedge funds and other institutional investors own 16.94% of the company’s stock.
About Fennec Pharmaceuticals
Fennec Pharmaceuticals Inc. is a specialty pharmaceutical company committed to the fight against ototoxicity in cancer patients who receive cisplatin-based chemotherapy. Fennec is focused on the commercialization of PEDMARK® to reduce the risk of platinum-induced ototoxicity in cancer patients. PEDMARK received FDA approval in September 2022 and European Commission approval in June 2023 and United Kingdom ( U.K. ) approval in October 2023 under the brand name PEDMARQSI®. In March 2024, Fennec entered into an exclusive licensing agreement under which Norgine Pharmaceuticals Ltd., a leading European specialist pharmaceutical company, with rights to commercialize PEDMARQSI® in Europe, U.K., Australia and New Zealand.
Read More
- Five stocks we like better than Fennec Pharmaceuticals
- Ondas Is Building a Defense Growth Engine, But Can It Deliver on Its Backlog?
- Orbiting Growth: Federal Contracts Boost Viasat’s Outlook
- Modine Manufacturing Scales Up to Solve the AI Heat Problem
- Nebius Revenue Is Surging, But Its Spending Is Raising Bigger Questions
Receive News & Ratings for Fennec Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fennec Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
